Completed PHASE3 INTERVENTIONAL 2-arm NCT00761761

Sensoril(Ashwaganhda)for Bipolar Disorder

Sensoril® (Ashwagandha) - A Standardized Extract From a Medicinal Plant - (Withania Somnifera) for Cognitive Enhancement in Persons With Bipolar Disorder: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study

Sponsor: National Alliance for Research on Schizophrenia and Depression

Conditions Bipolar Disorder NOS Bipolar I Disorder Bipolar II Disorder

Interventions Placebo Sensoril

Updated 6 times since 2017 Last updated: Mar 14, 2016 Started: Oct 31, 2008 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bipolar Disorder NOS and Bipolar I Disorder, this trial is completed. The trial is conducted by National Alliance for Research on Schizophrenia and Depression and has accumulated 6 data snapshots since 2008. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Alliance for Research on Schizophrenia and Depression
University of Pittsburgh

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States